145 related articles for article (PubMed ID: 31868884)
1. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression.
Endo H; Hama N; Baghdadi M; Ishikawa K; Otsuka R; Wada H; Asano H; Endo D; Konno Y; Kato T; Watari H; Tozawa A; Suzuki N; Yokose T; Takano A; Kato H; Miyagi Y; Daigo Y; Seino KI
Int Immunol; 2020 Mar; 32(3):175-186. PubMed ID: 31868884
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
[TBL] [Abstract][Full Text] [Related]
3. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Novel Benzenesulfonamide Analogue That Inhibits Proliferation and Metastasis Against Ovarian Cancer OVCAR-8 Cells.
Jia Y; Li M; Cao Y; Feng W; Li X; Xue W; Shi H
Drug Des Devel Ther; 2020; 14():207-216. PubMed ID: 32021105
[TBL] [Abstract][Full Text] [Related]
7. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
9. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
[TBL] [Abstract][Full Text] [Related]
11. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
12. Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway.
Xu M; Zhang Y
Anticancer Agents Med Chem; 2019; 19(18):2243-2250. PubMed ID: 31660844
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.
Zerbini LF; Tamura RE; Correa RG; Czibere A; Cordeiro J; Bhasin M; Simabuco FM; Wang Y; Gu X; Li L; Sarkar D; Zhou JR; Fisher PB; Libermann TA
PLoS One; 2011; 6(9):e24285. PubMed ID: 21931671
[TBL] [Abstract][Full Text] [Related]
16. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
17. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
18. Specific Cytostatic and Cytotoxic Effect of Dihydrochelerythrine in Glioblastoma Cells: Role of NF-κB/β-catenin and STAT3/IL-6 Pathways.
Silva TCC; de Faria Lopes GP; de J Menezes-Filho N; de Oliveira DM; Pereira E; Pitanga BPS; Dos Santos Costa R; da Silva Velozo E; Freire SM; Clarêncio J; Borges HL; Rehen SK; Moura-Neto V; Costa SL
Anticancer Agents Med Chem; 2018; 18(10):1386-1393. PubMed ID: 29651966
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
